The IFN-specific tachyphylaxis observed upon chronic STING activation, along with an immunosuppressive TME, might explain pre-existing resistance of chromosomally unstable tumours to STING agonists, which have thus far demonstrated limited efficacy in early-stage clinical trials despite evidence for adequate target engagement50,51. The gene discussed is IFNA1; the disease is neoplasm.